PARP抑制剂在卵巢癌治疗中的争议与临床未知因素
Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer.
作者信息
Mukherjee Uma A, Miller Rowan E, Ledermann Jonathan A
机构信息
Cancer Research UK and UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, UK.
University College London Hospital, London, UK.
出版信息
Ther Adv Med Oncol. 2025 Jun 14;17:17588359251343973. doi: 10.1177/17588359251343973. eCollection 2025.
Abstract
Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi) have significantly improved the treatment of advanced ovarian cancer, however, there are still many aspects of their use that require further understanding. The optimal duration, timing and dosage of these agents and how to manage (oligo) progression occurring both during and following PARPi therapy are discussed. The evidence supporting their rechallenge, and how to overcome resistance are addressed. The long-term impacts of PARPi and monitoring patients during therapy are all important research themes to expand on.
摘要
聚（二磷酸腺苷 - 核糖）聚合酶抑制剂（PARPi）显著改善了晚期卵巢癌的治疗，但在其使用方面仍有许多需要进一步了解的地方。本文讨论了这些药物的最佳使用持续时间、时机和剂量，以及如何处理PARPi治疗期间和之后出现的（寡）进展。文中还探讨了支持再次使用这些药物的证据以及如何克服耐药性。PARPi的长期影响以及治疗期间对患者的监测都是有待拓展的重要研究主题。
相似文献
1
Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer.
Ther Adv Med Oncol. 2025 Jun 14;17:17588359251343973. doi: 10.1177/17588359251343973. eCollection 2025.
2
Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians.
Respir Res. 2024 Dec 21;25(1):438. doi: 10.1186/s12931-024-03056-x.
3
Community views on mass drug administration for soil-transmitted helminths: a qualitative evidence synthesis.
Cochrane Database Syst Rev. 2025 Jun 20;6:CD015794. doi: 10.1002/14651858.CD015794.pub2.
4
Adapting Safety Plans for Autistic Adults with Involvement from the Autism Community.
Autism Adulthood. 2025 May 28;7(3):293-302. doi: 10.1089/aut.2023.0124. eCollection 2025 Jun.
5
"Just Ask What Support We Need": Autistic Adults' Feedback on Social Skills Training.
Autism Adulthood. 2025 May 28;7(3):283-292. doi: 10.1089/aut.2023.0136. eCollection 2025 Jun.
6
Interventions for fertility preservation in women with cancer undergoing chemotherapy.
Cochrane Database Syst Rev. 2025 Jun 19;6:CD012891. doi: 10.1002/14651858.CD012891.pub2.
7
Stigma Management Strategies of Autistic Social Media Users.
Autism Adulthood. 2025 May 28;7(3):273-282. doi: 10.1089/aut.2023.0095. eCollection 2025 Jun.
8
Anti-VEGF drugs compared with laser photocoagulation for the treatment of proliferative diabetic retinopathy: a systematic review and individual participant data meta-analysis.
Health Technol Assess. 2025 Apr 2:1-75. doi: 10.3310/MJYP6578.
9
Electronic cigarettes for smoking cessation.
Cochrane Database Syst Rev. 2025 Jan 29;1(1):CD010216. doi: 10.1002/14651858.CD010216.pub9.
10
Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation.
Target Oncol. 2025 May 21. doi: 10.1007/s11523-025-01146-4.
引用本文的文献
1
A Narrative Review of Clinical and Molecular Criteria for the Selection of Poor Candidates for Optimal Cytoreduction in Epithelial Ovarian Cancer.
Life (Basel). 2025 Aug 20;15(8):1318. doi: 10.3390/life15081318.
本文引用的文献
1
Long-term outcomes in the PRIMA trial: a closer look at progression-free survival and overall survival.
Ann Oncol. 2025 Mar;36(3):340. doi: 10.1016/j.annonc.2024.11.003. Epub 2024 Nov 12.
2
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.
Ann Oncol. 2025 Feb;36(2):185-196. doi: 10.1016/j.annonc.2024.10.828. Epub 2024 Nov 9.
3
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes.
Int J Gynecol Cancer. 2024 Dec 2;34(12):1932-1939. doi: 10.1136/ijgc-2024-005976.
4
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Ann Oncol. 2024 Nov;35(11):981-992. doi: 10.1016/j.annonc.2024.08.2241. Epub 2024 Sep 14.
5
To modulate or to skip: De-escalating PARP inhibitor maintenance therapy in ovarian cancer using adaptive therapy.
Cell Syst. 2024 Jun 19;15(6):510-525.e6. doi: 10.1016/j.cels.2024.04.003. Epub 2024 May 20.
6
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial.
Nat Med. 2024 Jun;30(6):1612-1621. doi: 10.1038/s41591-024-03003-9. Epub 2024 May 15.
7
Rational Design of PARP1/c-Met Dual Inhibitors for Overcoming PARP1 Inhibitor Resistance Induced by c-Met Overexpression.
J Med Chem. 2024 Mar 28;67(6):4916-4935. doi: 10.1021/acs.jmedchem.4c00077. Epub 2024 Mar 13.
8
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
J Clin Oncol. 2024 Apr 10;42(11):1301-1310. doi: 10.1200/JCO.23.01182. Epub 2024 Jan 12.
9
Role of Angiogenesis and Its Biomarkers in Development of Targeted Tumor Therapies.
Stem Cells Int. 2024 Jan 4;2024:9077926. doi: 10.1155/2024/9077926. eCollection 2024.
10
Secondary cytoreduction surgery for recurrent epithelial ovarian cancer patients after PARPi maintenance: A multicenter, randomized, controlled clinical trial.
Int J Gynecol Cancer. 2024 Feb 5;34(2):328-331. doi: 10.1136/ijgc-2023-004978.
Zotero 插件